2024
DengueSeq: a pan-serotype whole genome amplicon sequencing protocol for dengue virus
Vogels C, Hill V, Breban M, Chaguza C, Paul L, Sodeinde A, Taylor-Salmon E, Ott I, Petrone M, Dijk D, Jonges M, Welkers M, Locksmith T, Dong Y, Tarigopula N, Tekin O, Schmedes S, Bunch S, Cano N, Jaber R, Panzera C, Stryker I, Vergara J, Zimler R, Kopp E, Heberlein L, Herzog K, Fauver J, Morrison A, Michael S, Grubaugh N. DengueSeq: a pan-serotype whole genome amplicon sequencing protocol for dengue virus. BMC Genomics 2024, 25: 433. PMID: 38693476, PMCID: PMC11062901, DOI: 10.1186/s12864-024-10350-x.Peer-Reviewed Original ResearchMeSH KeywordsDengueDengue VirusGenome, ViralGenotypeHigh-Throughput Nucleotide SequencingHumansRNA, ViralSerogroupWhole Genome SequencingConceptsAmplicon sequencing protocolsPrimer schemeSequencing protocolGenomic surveillanceDengue virus serotypesAmplicon sequencing workflowClinical specimensHigh genome coverageWhole-genome sequencingDengue virusVirus serotypesGenome coverageVirus stocksGenetic diversitySequencing instrumentsSequencing workflowGenotype VIDiverse serotypesSequence of samplesGenotype IVPrimersSurveillance of dengue virusSerotypesVirus copiesSerotype-specific
2021
Metagenomics for surveillance of respiratory pathogens
Carr VR, Chaguza C. Metagenomics for surveillance of respiratory pathogens. Nature Reviews Microbiology 2021, 19: 285-285. PMID: 33707741, PMCID: PMC7950416, DOI: 10.1038/s41579-021-00541-8.Peer-Reviewed Original Research
2018
Emergence of Double- and Triple-Gene Reassortant G1P[8] Rotaviruses Possessing a DS-1-Like Backbone after Rotavirus Vaccine Introduction in Malawi
Jere KC, Chaguza C, Bar-Zeev N, Lowe J, Peno C, Kumwenda B, Nakagomi O, Tate JE, Parashar UD, Heyderman RS, French N, Cunliffe NA, Iturriza-Gomara M. Emergence of Double- and Triple-Gene Reassortant G1P[8] Rotaviruses Possessing a DS-1-Like Backbone after Rotavirus Vaccine Introduction in Malawi. Journal Of Virology 2018, 92: e01246-17. PMID: 29142125, PMCID: PMC5774894, DOI: 10.1128/jvi.01246-17.Peer-Reviewed Original ResearchConceptsRotavirus vaccineVaccine introductionVaccine effectivenessVaccine-induced neutralizing antibodiesMultiple African countriesRotavirus gastroenteritis casesRotavirus vaccine introductionChildhood immunization programsCareful evaluationVaccine escape mutantsDS-1-like backboneSuch atypical strainsRotavirus gastroenteritisImmunization scheduleNeutralizing antibodiesAmino acid substitutionsImmunization programsPostvaccine eraHigh burdenGastroenteritis casesImmune evasionEscape mutantsHuman WaDS-1-like rotavirusesRotavirus
2017
Population genetic structure, antibiotic resistance, capsule switching and evolution of invasive pneumococci before conjugate vaccination in Malawi
Chaguza C, Cornick JE, Andam CP, Gladstone RA, Alaerts M, Musicha P, Peno C, Bar-Zeev N, Kamng'ona AW, Kiran AM, Msefula CL, McGee L, Breiman RF, Kadioglu A, French N, Heyderman RS, Hanage WP, Bentley SD, Everett DB. Population genetic structure, antibiotic resistance, capsule switching and evolution of invasive pneumococci before conjugate vaccination in Malawi. Vaccine 2017, 35: 4594-4602. PMID: 28711389, PMCID: PMC5571440, DOI: 10.1016/j.vaccine.2017.07.009.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultBacterial CapsulesChildChild, PreschoolDrug Resistance, Multiple, BacterialEvolution, MolecularFemaleGenome, BacterialHigh-Throughput Nucleotide SequencingHumansInfantInfant, NewbornMalawiMalePneumococcal InfectionsPneumococcal VaccinesPrevalenceRetrospective StudiesSerogroupSerotypingStreptococcus pneumoniaeVaccinationVaccines, ConjugateYoung AdultConceptsPneumococcal conjugate vaccineMDR ratePneumococcal isolatesHigher MDR rateImplementation of PCV13Prevalence of serotypesNon-vaccine serotypesInvasive pneumococcal isolatesGood infection preventionAntibiotic resistance ratesAntibiotic resistanceAbsence of vaccinesReplacement serotypesSerotype replacementInvasive pneumococciPneumococcal infectionConjugate vaccineSerotype 12FDisease burdenInfection preventionSerotype prevalenceHigh prevalenceInvasive isolatesContinued surveillanceResistance rates